GCP
NTLA icon

GSA Capital Partners’s Intellia Therapeutics NTLA Stock Holding History

GSA Capital Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$234K Sell
13,823
-164,478
-92% -$2.3M 0.01% 1452
2026
Q1 		$2.29M Sell
178,301
-54,779
-24% -$698K 0.14% 120
2025
Q4 		$2.1M Buy
233,080
+157,989
+210% +$2.17M 0.18% 73
2025
Q3 		$1.3M Sell
75,091
-109,292
-59% -$1.35M 0.11% 255
2025
Q2 		$1.73M Sell
184,383
-35,535
-16% -$292K 0.12% 176
2025
Q1 		$1.56M Buy
219,918
+133,577
+155% +$1.35M 0.14% 147
2024
Q4 		$1.01M Buy
+86,341
New +$1.35M 0.07% 402
2024
Q3 		– Sell
-70,355
Closed -$1.57M – 1889
2024
Q2 		$1.57M Buy
+70,355
New +$1.68M 0.11% 248
2023
Q1 		– Sell
-14,355
Closed -$501K – 1794
2022
Q4 		$501K Buy
14,355
+3,948
+38% +$188K 0.06% 602
2022
Q3 		$582K Buy
+10,407
New +$646K 0.08% 459
2020
Q1 		– Sell
-33,533
Closed -$492K – 1398
2019
Q4 		$492K Buy
+33,533
New +$467K 0.06% 660
2019
Q3 		– Sell
-30,555
Closed -$500K – 1611
2019
Q2 		$500K Buy
30,555
+20,181
+195% +$317K 0.06% 668
2019
Q1 		$177K Buy
+10,374
New +$155K 0.02% 1263
2018
Q2 		– Sell
-51,900
Closed -$1.09M – 1854
2018
Q1 		$1.09M Buy
+51,900
New +$1.28M 0.06% 596
2017
Q4 		– Sell
-73,100
Closed -$1.82M – 1737
2017
Q3 		$1.82M Buy
73,100
+16,400
+29% +$309K 0.12% 182
2017
Q2 		$907K Buy
+56,700
New +$792K 0.06% 638

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

GSA Capital Partners's NTLA Position: Q2 2026 in Review

GSA Capital Partners reduced its Intellia Therapeutics (NTLA) stake by 92% in Q2 2026, selling an estimated $2.3M and leaving 13,823 shares worth $234K. The position accounts for 0.01% of the portfolio, ranked #1452.

GSA Capital Partners first reported a position in NTLA in Q2 2017 and has held it in 16 quarters since. The position peaked at $2.29M in Q1 2026. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • GSA Capital Partners held 13,823 shares of Intellia Therapeutics worth $234K as of Q2 2026.
  • GSA Capital Partners sold 164,478 Intellia Therapeutics shares in Q2 2026, an estimated $2.3M.
  • Intellia Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1452 holding.
  • GSA Capital Partners first reported a position in Intellia Therapeutics in Q2 2017 and has held it in 16 quarters since.
  • GSA Capital Partners's Intellia Therapeutics position peaked at $2.29M in Q1 2026.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.